You just read:

Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

News provided by

Daiichi Sankyo Company, Limited

06 Feb, 2018, 13:00 GMT